Intermediate Addition Multifocals Provide Good Gait Safety

This article originally appeared here.
Share this content:
Intermediate Addition Multifocals Provide Good Gait Safety
Intermediate Addition Multifocals Provide Good Gait Safety

MONDAY, Jan. 4, 2016 (HealthDay News) -- For healthy long-term multifocal wearers, intermediate addition progression-addition lenses (PALs) are associated with similar gait safety as distance single-vision spectacles, with improved ability to "spot read," according to a study published in the January issue of Ophthalmic & Physiological Optics.

David B. Elliott, Ph.D., from the University of Bradford in the United Kingdom, and colleagues examined whether intermediate addition multifocals could provide similar gait safety on stairs to distance vision spectacles, while providing adequate near vision. Fourteen healthy long-term multifocal wearers completed stair ascent and descent trials wearing intermediate and full addition bifocals and PALs.

The researchers found that, compared with intermediate bifocals and PALs, gait safety/caution measures were worse with full addition bifocals and PALs. Similar gait ascent/descent measures were seen for intermediate PALs and distance single-vision spectacles. Good reading ability was provided with the intermediate addition PALs; near word acuity and MNRead critical print size were better with intermediate addition PALs versus single-vision lenses (P < 0.0001). The mean near visual acuity with intermediate addition PALs was 0.24 ± 0.13 logMAR.

"A randomized controlled trial to investigate the usefulness of intermediate multifocals in preventing falls seems warranted," the authors write.

The study was supported by Essilor International R&D.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »